An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions

Hemophilia A, Severe

Interventions

BIOLOGICAL

SKP-0141

Human plasma-derived coagulation factor VIII concentrate

All Listed Sponsors

lead

SK Plasma Co., Ltd.

INDUSTRY